GlassScriptPhysician profile
Krystle Callan
NPI 1497592299
$1,923.06
in general payments reported to CMS, 2019-2025
33 companies · $1,808 in 2025
The $1,808 reported for 2025 was more than what 92% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $115 · 2025: $1,808.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,452 · Education: $471.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,452.11 |
| Education | $470.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $233.41 | 2025 | Darzalex, Talvey, Tecvayli |
| Novartis Pharmaceuticals Corporation | $203.21 | 2025 | |
| Incyte Corporation | $185.07 | 2025 | Jakafi, Monjuvi, Zynyz |
| Ipsen Biopharmaceuticals, INC | $161.11 | 2025 | Onivyde |
| Seagen INC. | $99.99 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $96.22 | 2025 | Fruzaqla, Vpriv, Iclusig |
| Bayer Healthcare Pharmaceuticals INC. | $87.48 | 2025 | |
| Lilly USA, LLC | $79.97 | 2025 | Jaypirca, Verzenio |
| Merck Sharp & Dohme LLC | $65.96 | 2024-2025 | Keytruda, Lynparza, Welireg |
| Alexion Pharmaceuticals, INC. | $53.14 | 2024-2025 | Ultomiris |
| Genentech USA, INC. | $47.99 | 2025 | Itovebi |
| Abbvie INC. | $46.97 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.48 | 2025 | |
| Novocure INC. | $40.20 | 2025 | Optune Gio |
| Galvanize Therapeutics, INC | $40.00 | 2025 | Aliya System |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $39.09 | 2025 | |
| Eisai INC. | $36.55 | 2024 | |
| Daiichi Sankyo INC. | $36.46 | 2025 | Enhertu |
| Astrazeneca Pharmaceuticals LP | $29.83 | 2025 | |
| Gilead Sciences, INC. | $27.89 | 2025 | Trodelvy |
| Nuvation Bio INC. | $27.67 | 2025 | Ibtrozi |
| Pharmacosmos Therapeutics INC. | $25.44 | 2025 | Monoferric |
| Genmab U.S., INC. | $24.98 | 2025 | Tivdak |
| Agios Pharmaceuticals, INC. | $22.95 | 2025 | Pyrukynd |
| Melinta Therapeutics, LLC | $21.08 | 2025 | Orbactiv, Kimyrsa, Rezzayo |
| Glaxosmithkline, LLC. | $20.44 | 2025 | Ojjaara |
| Kyowa Kirin, INC. | $20.24 | 2025 | |
| Legend Biotech USA INC. | $20.06 | 2025 | Carvykti |
| Azurity Pharmaceuticals, INC. | $19.81 | 2025 | Danziten |
| Puma Biotechnology, INC. | $19.27 | 2025 | |
| Shield Therapeutics INC | $16.63 | 2025 | |
| Pharmaessentia USA Corporation | $16.32 | 2025 | Besremi |
| Tolmar, INC. | $15.15 | 2025 | Eligard |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krystle Callan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.